Form 4: Heron Therapeutics Executive Granted Stock Options

Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, received employee stock options on April 28, 2025.

Summary

• Mark Earl Hensley, the Chief Operating Officer of Heron Therapeutics, Inc., was granted employee stock options on April 28, 2025.
• The options include both employee stock options (Right to Buy) for 500,000 shares and employee performance stock options (Right to Buy) for 900,000 shares, both with an exercise price of $2.33.
• The employee stock options vest over four years, with 125,000 shares vesting on the first anniversary and the remaining 375,000 vesting ratably each month over the subsequent three years.
• The employee performance stock options vest based on Heron Therapeutics' stock price reaching pre-established levels between $4.50 and $9.00 per share, contingent on Hensley's continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine corporate action, but the inclusion of performance-based options suggests confidence in the company's future prospects.

Positives

• The granting of performance-based stock options aligns executive compensation with company performance, incentivizing the COO to drive stock price appreciation.
• The vesting schedule encourages long-term commitment from the COO.

Risks

• The vesting of performance stock options is contingent on achieving specific stock price targets, which may not be met.
• The value of the options is dependent on the future stock price of Heron Therapeutics, which is subject to market fluctuations.

Future Outlook

The document does not contain specific forward-looking statements about the company's overall financial performance, but the vesting of performance-based options suggests an expectation of stock price appreciation.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and performance-based equity awards to incentivize their executives.
• The vesting schedules and performance metrics associated with these grants vary depending on the company's specific goals and circumstances.

Stakeholder Impact

• Shareholders may view the granting of performance-based stock options positively, as it aligns management's interests with stock price appreciation.
• Employees may be motivated by the potential for the company to achieve the stock price targets required for the performance options to vest.

Key Dates

Keywords

stock options, Heron Therapeutics, executive compensation, Form 4, Mark Earl Hensley, Chief Operating Officer, HRTX, vesting